^
    7ms
    DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Diakonos Oncology Corporation | Active, not recruiting --> Recruiting | N=43 --> 18 | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment open • Enrollment change • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)
    1year
    DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)
    almost2years
    Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma (clinicaltrials.gov)
    P1, N=17, Completed, The Cooper Health System | Recruiting --> Completed | Trial completion date: Dec 2025 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    dubodencel (DOC1021)
    almost2years
    DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Recruiting, Baylor College of Medicine
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)